Cardiovascular drug interactions with tyrosine kinase inhibitors

Détails

ID Serval
serval:BIB_C7693B91F4FA
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Titre
Cardiovascular drug interactions with tyrosine kinase inhibitors
Périodique
Cardiovascular Medicine
Auteur(s)
Haouala A., Widmer N., Montemurro M., Buclin T., Decosterd L.
ISSN
1092-8464
Statut éditorial
Publié
Date de publication
2010
Peer-reviewed
Oui
Volume
13
Numéro
5
Pages
147-154
Langue
anglais
Résumé
Imatinib mesylate, a selective inhibitor of tyrosine kinases, has excellent efficacy in the treatment of chronic myeloid leukaemia (CML) and gastrointestinal stromal tumour (GIST). Inducing durable responses and achieving prolonged survival, it has become the standard of care for the treatment of these diseases. It has opened the way to the development of additional tyrosine kinase inhibitors (TKIs), including sunitinib, nilotinib, dasatinib and sorafenib, all indicated for the treatment of various haematological malignancies and solid tumours. TKIs are prescribed for prolonged periods and are often taken by patients with - notably cardiovascular - comorbidities. Hence TKIs are regularly co-administered with cardiovascular drugs, with a considerable risk of potentially harmful drug-drug interactions due to the large number of agents used in combination. However, this aspect has received limited attention so far, and a comprehensive review of the published data on this important topic has been lacking. We review here the available data and pharmacological mechanisms of interactions between commonly prescribed cardiovascular drugs and the TKIs marketed at present. Regular updating of the literature on this topic will be mandatory, as will the prospective reporting of unexpected clinical observations, given the fact that these drugs have been only recently marketed.
Mots-clé
tyrosine kinase inhibitor, drug interactions, targeted cancer therapy, cytochrome P-450 enzyme, P-glycoprotein, gastrointestinal stromal tumour, chronic myeloid leukaemia, hepatocellular carcinoma, renal cell carcinoma
Création de la notice
17/12/2010 9:54
Dernière modification de la notice
20/08/2019 15:42
Données d'usage